for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aravive Inc

ARAV.OQ

Latest Trade

8.35USD

Change

0.27(+3.34%)

Volume

41,689

Today's Range

7.77

 - 

8.35

52 Week Range

3.07

 - 

9.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.08
Open
7.77
Volume
41,689
3M AVG Volume
0.53
Today's High
8.35
Today's Low
7.77
52 Week High
9.60
52 Week Low
3.07
Shares Out (MIL)
11.28
Market Cap (MIL)
94.23
Forward P/E
-4.68
Dividend (Yield %)
--

Next Event

Q3 2019 Aravive Inc Earnings Release

Latest Developments

More

Aravive Says Q2 Revenue $3.1 Million

Aravive Q1 Loss Per Share $0.42

Aravive Says Co May Offer Shares Of Common Stock Having Aggregate Offering Price Of Up To $20.25 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aravive Inc

Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.

Industry

Biotechnology & Drugs

Contact Info

1221 McKinney St Ste 3200

+1.936.3551910

https://www.versartis.com/

Executive Leadership

Srinivas Akkaraju

Independent Chairman of the Board

Jay P. Shepard

President, Chief Executive Officer, Director

Vinay Shah

Chief Financial Officer

Gail F. McIntyre

Chief Scientific Officer

Amato Giaccia

Independent Director

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-18.660

2017

-14.460

2019(E)

-1.785
Price To Earnings (TTM)
--
Price To Sales (TTM)
15.39
Price To Book (MRQ)
1.78
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-94.30
Return on Equity (TTM)
-88.75

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up